Submissions for variant NM_058216.3(RAD51C):c.634C>T (p.Arg212Cys)

gnomAD frequency: 0.00001  dbSNP: rs137947462

Total submissions: 8

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Labcorp Genetics (formerly Invitae), Labcorp	RCV000462369	SCV000550198	uncertain significance	Fanconi anemia complementation group O	2024-01-22	criteria provided, single submitter	clinical testing	This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 212 of the RAD51C protein (p.Arg212Cys). This variant is present in population databases (rs137947462, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with RAD51C-related conditions. ClinVar contains an entry for this variant (Variation ID: 409842). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on RAD51C protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics	RCV000567601	SCV000664918	uncertain significance	Hereditary cancer-predisposing syndrome	2024-06-25	criteria provided, single submitter	clinical testing	The p.R212C variant (also known as c.634C>T), located in coding exon 4 of the RAD51C gene, results from a C to T substitution at nucleotide position 634. The arginine at codon 212 is replaced by cysteine, an amino acid with highly dissimilar properties. Multiple functional studies on this alteration have demonstrated that it does not impact protein function (Prakash R et al. Proc Natl Acad Sci U S A, 2022 Sep;119:e2202727119; Hu C et al. Cancer Res, 2023 Aug;83:2557-2571). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear.
Color Diagnostics, LLC DBA Color Health	RCV000567601	SCV000686368	uncertain significance	Hereditary cancer-predisposing syndrome	2023-11-01	criteria provided, single submitter	clinical testing	This missense variant replaces arginine with cysteine at codon 212 of the RAD51C protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function. A functional study has reported that this variant does not impact RAD51C function in binding to other RAD51 paralogs and in a homology-directed repair assay (PMID: 36099300). This variant has been detected in a breast cancer case-control meta-analysis in 1/60466 cases and 0/53461 unaffected individuals (PMID: 33471991; Leiden Open Variation Database DB-ID RAD51C_000156) and among individuals with personal or family history of breast, ovarian or pancreatic cancer (PMID: 31742824). This variant has been identified in 9/282638 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
GeneDx	RCV001823139	SCV002072819	uncertain significance	not provided	2024-12-05	criteria provided, single submitter	clinical testing	Observed in an individual with a personal and/or family history of hereditary breast and ovarian cancer (PMID: 31742824); Published functional studies demonstrate protein interaction with RAD51 paralog comparable to wild type (PMID: 36099300); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 14704354, 36099300, 31742824)
Fulgent Genetics, Fulgent Genetics	RCV002506125	SCV002815921	uncertain significance	Breast-ovarian cancer, familial, susceptibility to, 3; Fanconi anemia complementation group O	2021-07-07	criteria provided, single submitter	clinical testing
KCCC/NGS Laboratory, Kuwait Cancer Control Center	RCV003239291	SCV003936137	uncertain significance	Breast-ovarian cancer, familial, susceptibility to, 3	2023-07-05	criteria provided, single submitter	clinical testing	This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 212 of the RAD51C protein (p.Arg212Cys). This variant observed in an individual with a personal and/or family history of hereditary breast and ovarian cancer (PMID: 14704354, 31742824, 36099300) also identified in 1/882 Chinese individuals who underwent multi-gene panel testing for HBOC risk assessment (Shao D et al. Cancer Sci, 2020 Feb;111:647-657). This variant is present in population databases (rs137947462, gnomAD 0.01%). ClinVar contains an entry for this variant (Variation ID: 409842). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Baylor Genetics	RCV003239291	SCV004208002	uncertain significance	Breast-ovarian cancer, familial, susceptibility to, 3	2024-03-19	criteria provided, single submitter	clinical testing
Mayo Clinic Laboratories, Mayo Clinic	RCV001823139	SCV005412796	uncertain significance	not provided	2024-06-28	criteria provided, single submitter	clinical testing	BS3_supporting